Prurigo Nodularis

Faculty & Disclosures

Dr Michele Ramien

Alberta Children’s Hospital in Calgary, Alberta, Canada

Michele L. Ramien, MD, is a Clinician-Investigator at the Alberta Children’s Hospital in Calgary, Alberta. Her practice is focused on the clinical care of medically or dermatologically complex children, with particular emphasis on patient and family-centered care in inflammation and health outcomes in rare diseases, and pharmacotherapy. She was involved in the development of a validated Eczema Action Plan initiative to facilitate effective, coordinated care of eczema for patients, doctors and pharmacists. She has published and presented at local, national and international congresses.

Dr Michele L. Ramien discloses: Research funding from Pediatric Dermatology Research Alliance. Speaker and/or consultant for AbbVie, Leo Pharma, Novartis, Pfizer, and Sanofi.

Dr Raj Chovatiya

Northwestern University Feinberg School of Medicine, Chicago, Illinois, US

Raj Chovatiya, MD, PhD, MSCI, is Assistant Professor of Dermatology at the Northwestern University Feinberg School of Medicine in Chicago. His research focus includes the intersection of cutaneous immunology and inflammatory disease, and he has a particular interest in optimizing patient-centered care, understanding chronic disease burden especially in understudied inflammatory diseases, and improving care across diverse skin types. He has published numerous abstracts and manuscripts.

Dr Raj Chovatiya discloses: Speaker, advisory board member, and/or investigator for AbbVie, Apogee Therapeutics, Arcutis, Argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Eli Lilly and Company, FIDE, Galderma, Genentech, GSK, Incyte, Janssen, LEO Pharma, L’Oréal, Nektar Therapeutics, Opsidio, Pfizer Inc., Regeneron, RAPT, Sanofi, and UCB.

Dr Thomas Casale

University of South Florida, Tampa, Florida, US

Thomas Casale, MD, is Professor of Medicine and Pediatrics, and Chief of Clinical and Translational Research at the University of South Florida Division of Allergy and Immunology in Tampa. His research interests include the determination and treatment of the pathophysiologic mechanisms involved in asthma, chronic obstructive pulmonary disease and allergic diseases, and has published over 500 scientific papers, reviews, and chapters on these topics. He is a Past President of the American Academy of Allergy Asthma and Immunology, and was Executive Vice President for 10 years.

Dr Thomas Casale discloses: Speaker, advisory board member, and/or investigator for AstraZeneca, American Lung Association, Boehringer Ingelheim, Genentech, NIH, Novartis, PCORI, Regeneron, and Sanofi.

Dr Eric Simpson

Oregon Health & Science University, Portland, Oregon, US

Eric Simpson, MD, MCR, is Professor of Dermatology Oregon Health & Science University. He is actively involved in clinical research to study new approaches to chronic skin disease treatment and prevention, and has published over 290 scientific articles in several high-impact peer-reviewed journals. He is serving as Chair of the NEA Research Advisory Committee.

Dr Eric Simpson discloses: Speaker, advisory board member, and/or investigator for AbbVie, Advances in Cosmetic Medical Derm Hawaii LLC, Amgen, AOBiome LLC, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aslan Pharma, Boehringer Ingelheim USA, Boston Consulting Group, Bristol Myers Squibb, Castle Biosciences, Collective Acumen LLC, CorEvitas, Dermavant, Dermira, Eli Lilly, Evelo Biosciences, Evidera, Excerpta Medica, FIDE, Galderma, Gesellschaft Z, GlaxoSmithKline, Incyte, Janssen, Johnson & Johnson, Kymab, Kyowa Kirin, LEO Pharma, Medscape LLC, Merck, Maui Derm, MLG Operating, MJH Holding, National Jewish Hospital, Pfizer, Physicians World LLC, PRIme, Regeneron, Revolutionizing Atopic Dermatitis, Roivant, Sanofi Target RWE, Trevi Therapeutics, Valeant, Vindico Medical Education, WebMD outside of submitted work.

Dr Amy Paller

Northwestern University, Evanston, Illinois, US

Amy Paller, MS, MD, is the Walter J. Hamlin Professor and Chair of Dermatology, Professor of Pediatrics, and Principal Investigator of the NIH-funded Skin Biology and Diseases Resource-based Center (SBDRC) at Northwestern. She is a lead investigator on several landmark trials in pediatric skin diseases and her research focuses on cell-cell communication in inflammatory skin diseases and impaired wound healing. She is current President of the International Society for Pediatric Dermatology, is an author of more than 600 peer-reviewed publications, and has written or edited several major textbooks in dermatology.

Dr Amy Paller discloses: Research funding from AbbVie, Applied Pharma Research, Dermavant, Eli Lilly, Incyte, Janssen, Krystal, Regeneron, and UCB. Speaker, advisory board member, and/or investigator for Aegerion Pharma, AbbVie, Abeona, Azitra, BioCryst, Boehringer Ingelheim, Bristol Myers Squibb, Castel Creek, Catawba, Eli Lilly, Gilead, InMed, Janssen, Krystal, LEO Pharma, Novartis, Regeneron, Sanofi/Genzyme, Seanergy (consultant with honorarium), TWI Biotechnology, and UCB.